NO179587C - Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt - Google Patents

Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt

Info

Publication number: NO179587C
Authority: NO; Norway
Prior art keywords: absent; lys; threonine; arg; aspartic acid
Prior art date: 1989-02-09

Application number

NO900615A

Other languages

English (en)

Other versions

NO900615L (no

NO900615D0 (no

NO179587B (no

Inventor

Ronald Eugene Chance

Richard Dennis Dimarchi

Bruce Hill Frank

James Edwin Shields

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1990-02-08

Publication date

1996-11-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO179587(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1990-02-08 Publication of NO900615D0 publication Critical patent/NO900615D0/no

1990-08-10 Publication of NO900615L publication Critical patent/NO900615L/no

1995-02-24 Priority to NO19950721A priority Critical patent/NO319171B1/no

1996-07-29 Publication of NO179587B publication Critical patent/NO179587B/no

1996-11-06 Publication of NO179587C publication Critical patent/NO179587C/no

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
239000004026 insulin derivative Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 5
239000004473 Threonine Substances 0.000 abstract 5
235000003704 aspartic acid Nutrition 0.000 abstract 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 5
235000009582 asparagine Nutrition 0.000 abstract 4
229960001230 asparagine Drugs 0.000 abstract 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
229930182821 L-proline Natural products 0.000 abstract 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
235000004279 alanine Nutrition 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
229960002429 proline Drugs 0.000 abstract 2
239000004474 valine Substances 0.000 abstract 2
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 abstract 1
JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 1
229930182820 D-proline Natural products 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 abstract 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
229940024606 amino acid Drugs 0.000 abstract 1
108010068380 arginylarginine Chemical group 0.000 abstract 1
108010062796 arginyllysine Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
235000004554 glutamine Nutrition 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
108010054155 lysyllysine Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
PMMYEEVYMWASQN-IUYQGCFVSA-N trans-4-hydroxy-D-proline Chemical compound O[C@@H]1CN[C@@H](C(O)=O)C1 PMMYEEVYMWASQN-IUYQGCFVSA-N 0.000 abstract 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/622—Insulins at least 1 amino acid in D-form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO900615A 1989-02-09 1990-02-08 Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt NO179587C (no)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NO19950721A NO319171B1 (no)	1989-02-09	1995-02-24	Rekombinant fremgangsmate for fremstilling av en terapeutisk aktiv insulinanalog.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30835289A	1989-02-09	1989-02-09
US38820189A	1989-08-04	1989-08-04

Publications (4)

Publication Number	Publication Date
NO900615D0 NO900615D0 (no)	1990-02-08
NO900615L NO900615L (no)	1990-08-10
NO179587B NO179587B (no)	1996-07-29
NO179587C true NO179587C (no)	1996-11-06

Family

ID=26976211

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO900615A NO179587C (no)	1989-02-09	1990-02-08	Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt
NO1996013C NO1996013I1 (no)	1989-02-09	1996-12-09	Insulinanalog

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO1996013C NO1996013I1 (no)	1989-02-09	1996-12-09	Insulinanalog

Country Status (24)

Country	Link
EP (2)	EP0383472B1 (no)
JP (1)	JPH0822878B2 (no)
KR (1)	KR0169727B1 (no)
CN (2)	CN1034080C (no)
AT (1)	ATE133961T1 (no)
AU (1)	AU630912B2 (no)
BG (1)	BG60769B2 (no)
CA (1)	CA2009579C (no)
CY (1)	CY1911A (no)
DE (3)	DE69025210T2 (no)
DK (2)	DK0383472T3 (no)
ES (2)	ES2170122T3 (no)
FI (1)	FI95915C (no)
GR (1)	GR3019501T3 (no)
HK (1)	HK60296A (no)
HU (2)	HU212679B (no)
IE (1)	IE73251B1 (no)
IL (1)	IL93282A (no)
LU (2)	LU88831I2 (no)
NL (1)	NL960026I2 (no)
NO (2)	NO179587C (no)
NZ (1)	NZ232375A (no)
PT (1)	PT93057B (no)
RU (1)	RU2109749C1 (no)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5716927A (en) *	1988-12-23	1998-02-10	Novo Nordisk A/S	Insulin analogs having a modified B-chain
HUT56857A (en) *	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence
DK10191D0 (da) *	1991-01-22	1991-01-22	Novo Nordisk As	Hidtil ukendte peptider
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
IL102240A0 (en) *	1991-06-21	1993-01-14	Lilly Co Eli	Insulin analogs
GB9316895D0 (en)	1993-08-13	1993-09-29	Guy S And St Thomas Hospitals	Hepatoselective insulin analogues
EP1607086A1 (en) *	1993-01-29	2005-12-21	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) *	1993-01-29	2000-10-17	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) *	1993-06-21	1993-06-21	Novo Nordisk As	Nyt produkt
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5504188A (en)	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5559094A (en) *	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs
US5547929A (en) *	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
US5597893A (en) *	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
US5646242A (en) *	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
EP0741188A3 (en) *	1995-05-05	1999-07-14	Eli Lilly And Company	Single chain insulin with high bioactivity
US5631347A (en) *	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
US5700904A (en) *	1995-06-07	1997-12-23	Eli Lilly And Company	Preparation of an acylated protein powder
BR9709845B1 (pt) *	1996-06-20	2008-11-18		preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
PT821006E (pt) *	1996-07-26	2004-09-30	Aventis Pharma Gmbh	Derivados de insulina com ligacao a zinco aumentada
SE520392C2 (sv)	1996-09-27	2003-07-01	Creative Peptides Sweden Ab C	Specifika peptider för behandling av diabetes mellitus
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001521006A (ja)	1997-10-24	2001-11-06	イーライ・リリー・アンド・カンパニー	不溶性インシュリン組成物
US6531448B1 (en)	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
US20010007853A1 (en) *	1998-01-08	2001-07-12	Dimarchi Richard Dennis	Method for administering monomeric insulin analogs
DE19805822B4 (de) *	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1125081C (zh) *	1999-09-08	2003-10-22	中国科学院上海生物化学研究所	重组天然和新型人胰岛素及其制备方法
US7202059B2 (en)	2001-02-20	2007-04-10	Sanofi-Aventis Deutschland Gmbh	Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en)	2001-02-20	2009-12-29	Sanofi-Aventis Deutschland Gmbh	Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003094951A1 (en) *	2002-05-07	2003-11-20	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en)	2002-10-29	2007-03-20	Sanofi-Aventis Deutschland Gmbh	Crystals of insulin analogs and processes for their preparation
RU2235776C1 (ru) *	2003-03-17	2004-09-10	Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова РАН	Рекомбинантная плазмидная днк plp-3,1, кодирующая полипептид проинсулина lyspro человека, и штамм бактерий escherichia coli plp-3-1/tg-1-продуцент рекомбинантного проинсулина lyspro
DK2275439T3 (da)	2003-08-05	2014-05-12	Novo Nordisk As	Hidtil ukendte insulinderivater
CA2531988C (en)	2003-08-05	2016-06-28	Novo Nordisk A/S	Novel insulin derivatives
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ES2373660T3 (es) *	2003-11-13	2012-02-07	Novo Nordisk A/S	Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
DK3300721T4 (da)	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
EP1692168B1 (en)	2003-12-03	2011-07-20	Novo Nordisk A/S	Single-chain insulin
RU2527893C2 (ru)	2004-07-19	2014-09-10	Биокон Лимитед	Инсулин-олигомерные конъюгаты, их препараты и применения
EP2256130B1 (en)	2005-02-02	2013-09-25	Novo Nordisk A/S	Novel insulin derivatives
US20080171695A1 (en)	2005-02-02	2008-07-17	Novo Nordisk A/S	Insulin Derivatives
EP1862174A1 (en) *	2005-03-02	2007-12-05	Ajinomoto Co., Inc.	Inhibitor for insulin polymer formation
CN102660614A (zh)	2005-08-16	2012-09-12	诺沃-诺迪斯克有限公司	制备成熟胰岛素多肽的方法
AU2006291780B2 (en)	2005-09-14	2011-12-08	F. Hoffmann-La Roche Ag	Cleavage of precursors of insulins by a variant of trypsin
ES2371361T3 (es)	2005-12-28	2011-12-30	Novo Nordisk A/S	Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de)	2006-02-27	2010-11-11	Novo Nordisk As	Insulinderivate
EP1996224B1 (en)	2006-03-15	2012-11-07	Novo Nordisk A/S	Mixtures of amylin and insulin
EP2015770B1 (en)	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulin derivative
WO2007128815A1 (en)	2006-05-09	2007-11-15	Novo Nordisk A/S	Insulin derivative
RU2524150C2 (ru)	2006-09-22	2014-07-27	Ново Нордиск А/С	Аналоги инсулина, устойчивые к протеазам
JP5496082B2 (ja)	2007-04-30	2014-05-21	ノボ・ノルデイスク・エー／エス	タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CN101677944A (zh)	2007-06-01	2010-03-24	诺沃-诺迪斯克有限公司	稳定的非含水药物组合物
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
RS59913B1 (sr) *	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
JP4959005B2 (ja)	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
US20120241356A1 (en)	2009-07-06	2012-09-27	Sanofi-Aventis Deutschland Gmbh	Heat- and vibration-stable insulin preparations
JP5675799B2 (ja)	2009-07-06	2015-02-25	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	遅効性インスリン製剤
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
NZ597964A (en)	2009-07-31	2014-04-30	Sanofi Aventis Deutschland	Long acting insulin composition
US9138462B2 (en)	2009-07-31	2015-09-22	Sanofi-Aventis Deutschland Gmbh	Prodrugs comprising an insulin linker conjugate
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MX2012012943A (es)	2010-05-10	2012-11-29	Novo Nordisk As	Proceso para preparacion de complejos de insulina-cinc.
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
EP2438930A1 (en)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrugs comprising an exendin linker conjugate
PL2632478T3 (pl)	2010-10-27	2020-03-31	Novo Nordisk A/S	Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN102199206B (zh) *	2011-03-17	2013-03-20	甘李药业股份有限公司	快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2014096985A2 (en)	2012-12-19	2014-06-26	Wockhardt Limited	A stable aqueous composition comprising human insulin or an analogue or derivative thereof
EP2844274B1 (en)	2012-05-01	2019-03-20	Novo Nordisk A/S	Pharmaceutical composition
US20130315891A1 (en)	2012-05-25	2013-11-28	Matthew Charles	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en)	2012-06-04	2013-12-05	Matthew Charles	Human tissue kallikrein 1 glycosylation isoforms
WO2014093696A2 (en)	2012-12-12	2014-06-19	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014161835A1 (en) *	2013-04-03	2014-10-09	Sanofi	Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
EP2991672A1 (en)	2013-04-30	2016-03-09	Novo Nordisk A/S	Novel administration regime
AU2014326181A1 (en)	2013-09-30	2016-03-17	Wockhardt Limited	Pharmaceutical composition
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
US10640546B2 (en) *	2014-06-10	2020-05-05	California Institute Of Technology	Non-canonical insulins and their uses
WO2016001862A1 (en)	2014-07-04	2016-01-07	Wockhardt Limited	Extended release formulations of insulins
EP3229828B1 (en)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
JP7158378B2 (ja) *	2016-09-23	2022-10-21	ハンミファーマシューティカルカンパニーリミテッド	インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
JP2019529506A (ja)	2016-09-29	2019-10-17	アレコルリミテッド	新規の製剤
AU2018230478B2 (en)	2017-03-09	2025-01-23	Diamedica Inc.	Dosage forms of tissue kallikrein 1
GB201707188D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707189D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707187D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
US12357562B2 (en)	2018-04-04	2025-07-15	Arecor Limited	Injection pen system for the delivery of an insulin compound
US20210113763A1 (en)	2018-04-04	2021-04-22	Arecor Limited	Medical infusion pump system for the delivery of an insulin compound
KR102833828B1 (ko)	2018-04-04	2025-07-15	아레콜 리미티드	인슐린 화합물의 전달을 위한 의료용 주입 펌프 시스템
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR20200082618A (ko)	2018-12-31	2020-07-08	주식회사 폴루스	인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
EP4086277A4 (en)	2019-12-30	2024-02-14	Gan & Lee Pharmaceuticals Co., Ltd.	Long-acting glp-1 compound
CN118754967A (zh)	2019-12-30	2024-10-11	甘李药业股份有限公司	胰岛素衍生物
GB202004814D0 (en)	2020-04-01	2020-05-13	Arecor Ltd	Novel formulations
US20250340610A1 (en)	2022-01-28	2025-11-06	Gan & Lee Pharmaceuticals Co., Ltd.	Acylated insulin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3101382A1 (de) *	1981-01-17	1982-09-02	Hoechst Ag, 6000 Frankfurt	"verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence

1990
- 1990-02-05 IL IL9328290A patent/IL93282A/en not_active IP Right Cessation
- 1990-02-05 NZ NZ232375A patent/NZ232375A/en unknown
- 1990-02-05 PT PT93057A patent/PT93057B/pt active IP Right Grant
- 1990-02-06 LU LU88831C patent/LU88831I2/fr unknown
- 1990-02-06 DE DE69025210T patent/DE69025210T2/de not_active Expired - Lifetime
- 1990-02-06 DK DK90301224.3T patent/DK0383472T3/da active
- 1990-02-06 DE DE1990625210 patent/DE19675034I2/de active Active
- 1990-02-06 DK DK95200804T patent/DK0678522T3/da active
- 1990-02-06 LU LU88830C patent/LU88830I2/fr unknown
- 1990-02-06 CY CY191190A patent/CY1911A/xx unknown
- 1990-02-06 DE DE69033889T patent/DE69033889T2/de not_active Expired - Lifetime
- 1990-02-06 EP EP90301224A patent/EP0383472B1/en not_active Expired - Lifetime
- 1990-02-06 AT AT90301224T patent/ATE133961T1/de active
- 1990-02-06 ES ES95200804T patent/ES2170122T3/es not_active Expired - Lifetime
- 1990-02-06 EP EP95200804A patent/EP0678522B1/en not_active Expired - Lifetime
- 1990-02-06 ES ES90301224T patent/ES2083424T3/es not_active Expired - Lifetime
- 1990-02-07 AU AU49226/90A patent/AU630912B2/en not_active Expired
- 1990-02-07 FI FI900600A patent/FI95915C/fi active IP Right Grant
- 1990-02-07 IE IE44090A patent/IE73251B1/en not_active IP Right Cessation
- 1990-02-08 KR KR1019900001498A patent/KR0169727B1/ko not_active Expired - Lifetime
- 1990-02-08 JP JP2031347A patent/JPH0822878B2/ja not_active Expired - Lifetime
- 1990-02-08 NO NO900615A patent/NO179587C/no not_active IP Right Cessation
- 1990-02-08 CN CN90101415A patent/CN1034080C/zh not_active Expired - Lifetime
- 1990-02-08 HU HU90726A patent/HU212679B/hu unknown
- 1990-02-08 CA CA002009579A patent/CA2009579C/en not_active Expired - Lifetime
1991
- 1991-11-21 RU SU5010208A patent/RU2109749C1/ru active
1994
- 1994-02-25 BG BG098572A patent/BG60769B2/bg unknown
1995
- 1995-06-07 HU HU95P/P00171P patent/HU211276A9/hu unknown
1996
- 1996-04-02 GR GR960400889T patent/GR3019501T3/el unknown
- 1996-04-03 HK HK60296A patent/HK60296A/en not_active IP Right Cessation
- 1996-05-23 CN CN96106635A patent/CN1103602C/zh not_active Ceased
- 1996-10-17 NL NL960026C patent/NL960026I2/nl unknown
- 1996-12-09 NO NO1996013C patent/NO1996013I1/no unknown

Also Published As

Publication number	Publication date
BG60769B2 (bg)	1996-02-29
EP0678522A1 (en)	1995-10-25
NO1996013I1 (no)	1996-12-09
DE69025210D1 (de)	1996-03-21
KR0169727B1 (ko)	1999-01-15
JPH0822878B2 (ja)	1996-03-06
DE19675034I2 (de)	2006-11-16
NO900615L (no)	1990-08-10
NL960026I2 (nl)	1997-05-01
EP0383472A3 (en)	1991-09-18
NO900615D0 (no)	1990-02-08
ES2083424T3 (es)	1996-04-16
DE69033889T2 (de)	2002-08-22
EP0383472B1 (en)	1996-02-07
ES2170122T3 (es)	2002-08-01
CY1911A (en)	1990-02-06
FI95915C (fi)	1996-04-10
IL93282A0 (en)	1990-11-29
IE73251B1 (en)	1997-05-21
HUT57795A (en)	1991-12-30
PT93057A (pt)	1990-08-31
HU900726D0 (en)	1990-04-28
ATE133961T1 (de)	1996-02-15
EP0383472A2 (en)	1990-08-22
CN1103602C (zh)	2003-03-26
CA2009579A1 (en)	1990-08-09
RU2109749C1 (ru)	1998-04-27
EP0678522B1 (en)	2002-01-02
LU88830I2 (fr)	1997-01-06
IE900440L (en)	1990-08-09
DK0678522T3 (da)	2002-03-11
CA2009579C (en)	2000-04-11
HK60296A (en)	1996-04-12
CN1044820A (zh)	1990-08-22
NO179587B (no)	1996-07-29
PT93057B (pt)	1995-12-29
HU211276A9 (en)	1995-11-28
IL93282A (en)	1995-08-31
FI95915B (fi)	1995-12-29
NL960026I1 (nl)	1997-01-06
FI900600A0 (fi)	1990-02-07
CN1034080C (zh)	1997-02-19
KR900012627A (ko)	1990-09-01
CN1148984A (zh)	1997-05-07
DK0383472T3 (da)	1996-05-06
DE69033889D1 (de)	2002-02-07
AU4922690A (en)	1990-08-16
NZ232375A (en)	1992-04-28
JPH02264798A (ja)	1990-10-29
DE69025210T2 (de)	1996-06-13
GR3019501T3 (en)	1996-07-31
HU212679B (en)	1996-09-30
AU630912B2 (en)	1992-11-12
LU88831I2 (fr)	1997-01-10

Legal Events

Date	Code	Title	Description
2010-02-22	MK1K	Patent expired

Publication	Publication Date	Title
NO179587C (no)	1996-11-06	Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt
EP0512042A4 (en)	1993-02-17	Glp-1 analogs useful for diabetes treatment
HU906177D0 (en)	1991-08-28	Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
NZ517012A (en)	2003-02-28	Peptides that lower blood glucose levels
CA2207078A1 (en)	1998-01-26	Insulin derivatives with increased zinc binding
PE47096A1 (es)	1996-11-12	Analogo, composicion y uso del peptido insulinotropico similar al glucagon
WO2002048180A3 (de)	2003-01-30	Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
FI925972A0 (fi)	1992-12-31	Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning
KR910002899A (ko)	1991-02-26	혈조절 펩타이드
AU1496888A (en)	1988-11-02	Biologically active molecules
CA2102606A1 (en)	1992-11-09	Compositions for the treatment of chronic fatigue syndrome
DE69302921D1 (de)	1996-07-11	Neue Peptidderivate, Verfahren zu deren Herstellung und deren Anwendung als Heilmittel
ES2135389T3 (es)	1999-11-01	Antagonistas de endotelina.
RU93004930A (ru)	1996-01-27	Днк, соматотропин, плазмиды, рекомбинантные организмы, композиция, способ получения соматотропина, способы стимулирования роста